Hurdles and complexities of codon 13 KRAS mutations

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3565-3567

  Morelli, Maria Pia ^a   Kopetz, Scott ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GLYCINE; GUANOSINE TRIPHOSPHATE; K RAS PROTEIN; PANITUMUMAB; TUMOR MARKER;

CANCER CELL; CANCER SURVIVAL; CLINICAL PRACTICE; CODON; COLORECTAL CANCER; DENDRITIC CELL; EDITORIAL; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CODON; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTATION; NEEDS ASSESSMENT; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84867605846     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6535     Document Type: Editorial

References (16)

1. Tejpar S, Celik I, Schlichting M, et al: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570-3577, 2012
2. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005 (Pubitemid 46211358)
3. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008 (Pubitemid 351171687)
4. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
5. Camp ER, Summy J, Bauer TW, et al: Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11:397-405, 2005 (Pubitemid 40075820)
6. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
7. Peeters M, Douillard J-Y, Van Cutsem E, et al: Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). J Clin Oncol 30, 2012 (suppl 15; abstr 3581)
8. Peeters M, Douillard J, Van Cutsem E, et al: Evaluation of individual codon 12 and 13 mutant (mt) KRAS alleles as prognostic and predictive biomarkers of response to panitumumab (pmab) in patients with metastatic colorectal cancer (mCRC). Eur J Cancer 47, 2011 (suppl 2; abstr LBA33)
9. Guerrero S, Casanova I, Farré L, et al: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60:6750-6756, 2000
10. Kraus MC, Seelig MH, Linnemann U, et al: The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues. Int J Oncol 29:957-964, 2006
11. Modest DP, Stintzing S, Laubender RP, et al: Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 22:913-918, 2011
12. Kocián P, Šedivcová M, Drgáč J, et al: Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence. Hum Immunol 72:1022-1028, 2011
13. Samowitz WS, Curtin K, Schaffer D, et al: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev 9:1193-1197, 2000
14. Sylvester BE, Huo D, Khramtsov A, et al: Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 18:350-359, 2012
15. Oliveira C, Westra JL, Arango D, et al: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 13:2303-2311, 2004 (Pubitemid 39359927)
16. Kampman E, Voskuil DW, van Kraats AA, et al: Animal products and K-ras codon 12 and 13 mutations in colon carcinomas. Carcinogenesis 21:307-309, 2000 (Pubitemid 30098718)